Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of “Reduce” by Brokerages

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received an average rating of “Reduce” from the seven research firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $15.00.

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Truist Financial restated a “hold” rating and issued a $13.00 price objective (down previously from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. Citigroup reduced their target price on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in Integra LifeSciences by 55.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 913 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Integra LifeSciences by 205.9% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock worth $38,000 after purchasing an additional 2,108 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares in the last quarter. AlphaQuest LLC purchased a new position in Integra LifeSciences during the 2nd quarter worth $73,000. Finally, EMC Capital Management acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at $75,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Up 2.8%

Shares of NASDAQ:IART opened at $11.08 on Thursday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14. The firm has a fifty day moving average of $12.59 and a 200 day moving average of $13.34. Integra LifeSciences has a 52-week low of $10.65 and a 52-week high of $26.98. The firm has a market capitalization of $863.02 million, a PE ratio of -1.72 and a beta of 1.04.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.